{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:40:23Z","timestamp":1783464023881,"version":"3.55.0"},"reference-count":57,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Pulmonary hypertension (PH) is a progressive disorder with high morbidity and mortality, partly driven by chronic inflammation. Soluble urokinase plasminogen activator receptor (suPAR) reflects immune activation. We evaluated whether suPAR is altered in Group 1 and Group 4 PH and its association with clinical, echocardiographic, and laboratory parameters. Methods: We enrolled 44 PH patients (36 in Group 1, 8 in Group 4) and 45 healthy controls. All underwent clinical and echocardiographic assessments; right heart catheterization was performed in the PH patients. Serum suPAR was measured by ELISA. N-terminal pro B-type natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) were also assessed. Results: The suPAR plasma levels in the PH group were between 23.91 and 960.8 pg\/mL (median: 73.14 p25: 62.77, p75: 167.13). suPAR was significantly higher in PH versus controls (73.14 [62.77\u2013167.13] vs. 65.52 [53.06\u201380.91] pg\/mL; p = 0.012). In logistic regression, systolic blood pressure, erythrocyte sedimentation rate, NT-proBNP, and suPAR independently predicted PH. suPAR correlated negatively with six-minute walk distance (r = \u22120.310) and tricuspid annular plane systolic excursion (r = \u22120.295) but positively with systolic pulmonary artery pressure (r = 0.241). On multivariate analysis, six-minute walk distance was the only independent correlate of suPAR (p = 0.004). suPAR levels did not differ between Group 1 and Group 4 PH. Conclusions: suPAR is elevated in Group 1 and Group 4 PH and correlates with functional and echocardiographic indices of disease severity. Larger prospective studies are needed to determine suPAR\u2019s role in diagnosis, risk stratification, and therapeutic decision-making.<\/jats:p>","DOI":"10.3390\/jcm14134671","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T04:11:04Z","timestamp":1751429464000},"page":"4671","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Assessment of Serum suPAR Levels in Patients with Group 1 and Group 4 Pulmonary Hypertension"],"prefix":"10.3390","volume":"14","author":[{"given":"Abdullah","family":"Tun\u00e7ez","sequence":"first","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Ulvi","family":"Yal\u00e7\u0131n","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-874X","authenticated-orcid":false,"given":"H\u00fcseyin","family":"Tezcan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent Behl\u00fcl","family":"Altunkeser","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2654-7621","authenticated-orcid":false,"given":"Bahad\u0131r","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canan","family":"Aydo\u011fan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131han","family":"Toprak","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur Can","family":"Polat","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-231X","authenticated-orcid":false,"given":"Nazif","family":"Ayg\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenan","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri Murat","family":"G\u00fcrses","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"\u00d6zen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fikret","family":"Aky\u00fcrek","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice Bet\u00fcl","family":"Tun\u00e7ez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Medicine, Sel\u00e7uk University, 42130 Sel\u00e7uklu-Konya, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_2","first-page":"322","article-title":"Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey","volume":"21","author":"Yaylali","year":"2019","journal-title":"Anatol. J. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01032-2015","article-title":"2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)","volume":"46","author":"Galie","year":"2015","journal-title":"Eur. Respir. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_6","first-page":"35","article-title":"Pulmonary hypertension experience in an expert university hospital","volume":"20","author":"Sinan","year":"2018","journal-title":"Anatol. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1378\/chest.11-0793","article-title":"Inflammation in pulmonary arterial hypertension","volume":"141","author":"Price","year":"2012","journal-title":"Chest"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1164\/rccm.201202-0335OC","article-title":"Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension","volume":"186","author":"Savai","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.201201-0164OC","article-title":"Modern age pathology of pulmonary arterial hypertension","volume":"186","author":"Stacher","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/CIRCULATIONAHA.106.655837","article-title":"Diverse contribution of bone marrow-derived cells to vascular remodeling associated with pulmonary arterial hypertension and arterial neointimal formation","volume":"115","author":"Sahara","year":"2007","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.00094706","article-title":"Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension","volume":"29","author":"Perros","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1183\/09031936.00151313","article-title":"Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension","volume":"43","author":"Cracowski","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1121143","article-title":"Structure of human urokinase plasminogen activator in complex with its receptor","volume":"311","author":"Huai","year":"2006","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1155\/2009\/504294","article-title":"suPAR: The molecular crystal ball","volume":"27","author":"Thuno","year":"2009","journal-title":"Dis. Markers"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Ni, W., Han, Y., Zhao, J., Cui, J., Wang, K., Wang, R., and Liu, Y. (2016). Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: A systematic review and meta-analysis. Sci. Rep., 6.","DOI":"10.1038\/srep39481"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3109\/0284186X.2010.491086","article-title":"Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients","volume":"49","author":"Lomholt","year":"2010","journal-title":"Acta Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1478-3231.2011.02665.x","article-title":"Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and aetiology of cirrhosis and predicts prognosis","volume":"32","author":"Zimmermann","year":"2012","journal-title":"Liver Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ejhf.49","article-title":"Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation","volume":"16","author":"Borne","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2796.2010.02252.x","article-title":"Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population","volume":"268","author":"Andersen","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jneuroim.2004.08.038","article-title":"Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease","volume":"157","author":"Sidenius","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa1506362","article-title":"Soluble Urokinase Receptor and Chronic Kidney Disease","volume":"373","author":"Hayek","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2011.10.039","article-title":"Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study","volume":"220","author":"Persson","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e001118","DOI":"10.1161\/JAHA.114.001118","article-title":"Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events","volume":"3","author":"Eapen","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2014.08.035","article-title":"Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects","volume":"237","author":"Sorensen","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2014.12.025","article-title":"Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease","volume":"239","author":"Mekonnen","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2016.12.008","article-title":"Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure","volume":"5","author":"Koller","year":"2017","journal-title":"JACC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.cjca.2016.04.012","article-title":"SuPAR Predicts Cardiovascular Events and Mortality in Patients With Asymptomatic Aortic Stenosis","volume":"32","author":"Hodges","year":"2016","journal-title":"Can. J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.amjcard.2012.08.008","article-title":"Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention","volume":"110","author":"Lyngbaek","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s10096-011-1236-8","article-title":"Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia","volume":"30","author":"Molkanen","year":"2011","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000488908","article-title":"Neopterin as a Biomarker in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension","volume":"96","author":"Marcinkowska","year":"2018","journal-title":"Respiration"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5152\/balkanmedj.2014.13307","article-title":"Serum Pentraxin 3 and hs-CRP Levels in Children with Severe Pulmonary Hypertension","volume":"31","author":"Karakurt","year":"2014","journal-title":"Balk. Med. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.hlc.2016.12.012","article-title":"Galectin-3 Levels Are Elevated and Predictive of Mortality in Pulmonary Hypertension","volume":"26","author":"Mazurek","year":"2017","journal-title":"Heart Lung Circ."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1801915","DOI":"10.1183\/13993003.01915-2018","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"53","author":"Kim","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"H1322","DOI":"10.1152\/ajpheart.00136.2018","article-title":"Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension","volume":"315","author":"Thenappan","year":"2018","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra035488","article-title":"Pulmonary arterial hypertension","volume":"351","author":"Farber","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/ATVBAHA.116.307634","article-title":"Neutrophil Extracellular Traps Promote Angiogenesis: Evidence From Vascular Pathology in Pulmonary Hypertension","volume":"36","author":"Aldabbous","year":"2016","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1801900","DOI":"10.1183\/13993003.01900-2018","article-title":"Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: An update","volume":"53","author":"Chin","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: Results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: Baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2017.01.015","article-title":"Survival of Japanese Patients With Idiopathic\/Heritable Pulmonary Arterial Hypertension","volume":"119","author":"Ogawa","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/resp.13392","article-title":"Pulmonary arterial hypertension in a multi-ethnic Asian population: Characteristics, survival and mortality predictors from a 14-year follow-up study","volume":"24","author":"Lim","year":"2019","journal-title":"Respirology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: Prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"Eur. Respir. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","article-title":"A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension","volume":"39","author":"Kylhammar","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2045894019877157","DOI":"10.1177\/2045894019877157","article-title":"Epidemiology and initial management of pulmonary arterial hypertension: Real-world data from the Hellenic pulmOnary hyPertension rEgistry (HOPE)","volume":"9","author":"Arvanitaki","year":"2019","journal-title":"Pulm. Circ."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.atherosclerosis.2018.01.029","article-title":"Prognostic value of suPAR and hs-CRP on cardiovascular disease","volume":"271","author":"Diederichsen","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s00134-012-2613-1","article-title":"Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: A systematic review","volume":"38","author":"Backes","year":"2012","journal-title":"Intensive Care Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1161\/01.CIR.103.15.2014","article-title":"Deficiency of urokinase-type plasminogen activator-mediated plasmin generation impairs vascular remodeling during hypoxia-induced pulmonary hypertension in mice","volume":"103","author":"Levi","year":"2001","journal-title":"Circulation"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2011.10.044","article-title":"The urokinase system in the pathogenesis of atherosclerosis","volume":"222","author":"Fuhrman","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1165\/ajrcmb.22.3.3713","article-title":"Nonproteolytic role for the urokinase receptor in cellular migration in vivo","volume":"22","author":"Waltz","year":"2000","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Kruger, R., Rasmussen, L.M., Argraves, W.S., Eugen-Olsen, J., Nielsen, O.W., Blyme, A., Willenheimer, R., Wachtell, K., and Olsen, M.H. (2014). Extracellular matrix biomarker, fibulin-1, is closely related to NT-proBNP and soluble urokinase plasminogen activator receptor in patients with aortic valve stenosis (the SEAS study). PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101522"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.hlc.2014.09.019","article-title":"Extracellular matrix biomarker, fibulin-1 and its association with soluble uPAR in a bi-ethnic South African population: The SAfrEIC study","volume":"24","author":"Kruger","year":"2015","journal-title":"Heart Lung Circ."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1161\/ATVBAHA.118.312254","article-title":"Macrophage-Derived Legumain Promotes Pulmonary Hypertension by Activating the MMP (Matrix Metalloproteinase)-2\/TGF (Transforming Growth Factor)-beta1 Signaling","volume":"39","author":"Bai","year":"2019","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1515\/cclm-2015-0079","article-title":"Increased plasma soluble urokinase plasminogen activator receptor levels in systemic sclerosis: Possible association with microvascular abnormalities and extent of fibrosis","volume":"53","author":"Legany","year":"2015","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Butt, S., Jeppesen, J.L., Iversen, L.V., Fenger, M., Eugen-Olsen, J., Andersson, C., and Jacobsen, S. (2021). Association of soluble urokinase plasminogen activator receptor levels with fibrotic and vascular manifestations in systemic sclerosis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247256"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e032888","DOI":"10.1161\/JAHA.123.032888","article-title":"Prognostic Significance of Proteomics-Discovered Circulating Inflammatory Biomarkers in Patients With Pulmonary Arterial Hypertension","volume":"13","author":"Yokokawa","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.hlc.2019.03.004","article-title":"Analysis of Novel Cardiovascular Biomarkers in Patients With Pulmonary Hypertension (PH)","volume":"29","author":"Mirna","year":"2019","journal-title":"Heart Lung Circ."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4671\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:44Z","timestamp":1760032964000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/13\/4671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":57,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["jcm14134671"],"URL":"https:\/\/doi.org\/10.3390\/jcm14134671","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]}}}